secwatch.observer — SEC 8-K summary
======================================

Issuer:     Genprex, Inc. (GNPX)
CIK:        0001595248
Form:       8-K
Filed at:   2026-04-28T23:59:59+00:00
Accession:  0001437749-26-013534
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Genprex' GPX-002 reverses hyperglycemia in T2D mouse models; data at ASGCT 2026
-------------------------------------------------------------------------------

- GPX-002 (Pdx1/MafA gene therapy) reversed hyperglycemia in HFD-induced T2D mouse models within 4 weeks post-treatment.
- Islets from treated mice showed insulin secretion similar to normal-diet mice; improved beta-cell function and maturation.
- Treatment increased mature insulin granules and decreased immature granules in beta cells.
- Approach deemed potentially translatable to humans via endoscopic retrograde cholangiopancreatography (ERCP).
- Data to be presented at ASGCT Annual Meeting, May 11-15, 2026 in Boston.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1595248/000143774926013534/0001437749-26-013534-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1595248/000143774926013534/gnpx20260424_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-013534

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer